ClinicalTrials.gg
Active, not recruitingNCT05335252Updated Sep 25, 2026

Dronabinol After Arthroscopic Surgery

A Phase 3 interventional study of Dronabinol and Placebo in Knee Osteoarthritis, Knee Injuries and Meniscus Tear, sponsored by Northwestern University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Northwestern University · Phase 3, Interventional, and Treatment

How we know

Updated Sep 25, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Osteoarthritis, Knee by Northwestern University — 3 open to participants now, 5 under way, 1 of them phase 3. Osteoarthritis, Knee · Northwestern University.

Planned enrollment
8th of 12
30 · median 50
Started
2022
with 1 other
Phase 3
Only one
of the 12
Registered
7th of 12
by date

Among the 12 studies in Osteoarthritis, Knee by Northwestern University, this one is the 8th largest by planned enrollment, is one of 2 that started in 2022, is the only one in phase 3, and was the 7th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 12 studies in Osteoarthritis, Knee by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Osteoarthritis, Knee by Northwestern University, or all of them as a file.
02

Study summary

The purpose of the proposed study is to evaluate the efficacy of dronabinol for postoperative pain after arthroscopic surgery of the knee. The investigators hypothesize that dronabinol will relieve pain, reduce opioid consumption and will result in few negative side effects. If this pilot study shows promising results the investigators will expand the trial to include additional arthroscopic surgeries (hip, shoulder) and other types of orthopaedic surgery.

03

Conditions studied

  • Knee Osteoarthritis
  • Knee Injuries
  • Meniscus Tear
  • Synovitis of Knee
  • Knee Ligament Injury
  • Chondral Injury of Left Knee
  • Chondral Injury of Right Knee
  • Loose Body Knee

Keywords

  • Knee Arthroscopy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Patient who will undergo arthroscopic surgery of the knee including, but not limited to,

    • Meniscectomy
    • Synovectomy
    • Chondroplasty
    • Loose body removal

Exclusion criteria

Exclusion Criteria:

  • Patients under age 18 years
  • Patients who cannot provide consent
  • Patients who are pregnant, breast feeding, or are trying to become pregnant during the study period
  • Patients with an allergy to any of the study drugs
  • Patient who are lactose-intolerant
  • Revision surgery
  • Open surgery
  • Comorbidities preventing surgery
  • Patients with a history of mania, depression, or schizophrenia
  • Patients taking any of the following drugs or supplements

    • Anticholinergic agents
    • Benzodiazepines
    • Central nervous system depressants
    • Droperidol
    • Hydroxyzine
    • Levomepromazine or methotrimeprazine
    • Monoamine oxidase inhibitors
    • Ritonavir
    • Selective serotonin reuptake inhibitors
    • Sympathomimetics
    • St. John's Wort
  • Current diagnosed alcohol or drug abuse
  • Patients who cannot or will not abide by the medication restrictions listed below

Medication restrictions

  • Participants must agree to abstain from using recreational or medical marijuana products or cannabidiol (CBD) in any form during the treatment period
  • Participants should not drink alcohol or take other drugs while taking the study drug or hydrocodone/acetaminophen
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Dronabinol

    Patients will received dronabinol (5mg) twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery

    Drug: Dronabinol

  • Placebo comparator
    Placebo

    Patients will received placebo twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery

    Drug: Placebo

Interventions

  • 5mg 2x daily for 7 days

    Also known as: Marinol

  • DrugPlacebo

    1 caplet 2x daily for 7 days

06

What researchers measure

Primary outcomes

  1. Opioid consumption

    Count of number of hydrocodone/acetaminophen tablet consumed

    Time frame: up to 7 days post-surgery

Secondary outcomes

  1. Pain Visual Analog Scale (VAS)

    Scored from 0 (no pain) to 10 (worst possible pain)

    Time frame: up to 7 days post-surgery

  2. Patient-Reported Outcomes Measurement Information System (PROMIS) Bank v1.1 - Pain Interference

    PROMIS measures generate T-scores. T-scores are standard scores with a mean of 50 and standard deviation of 10 in a reference population (usually U.S. general population). A low score indicates less pain interference (better outcome) and a high score indicates more pain interference (worse outcome).

    Time frame: up to 21 days post-surgery

  3. PROMIS Bank v2.0 - Pain Behavior

    PROMIS measures generate T-scores. T-scores are standard scores with a mean of 50. A low score indicates less pain (better outcome) and a high score indicates more pain (worse outcome).

    Time frame: up to 21 days post-surgery

  4. PROMIS Bank v2.0 - Physical Function

    PROMIS measures generate T-scores. T-scores are standard scores with a mean of 50. A low score indicates worse physical functioning and a high score indicates better physical functioning.

    Time frame: up to 21 days post-surgery

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2027, 66 months after the start.

Of 36 non-industry phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 66 months is above that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Dec 2026 → Dec 2027 and completion Jun 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2022
First posted
Apr 19, 2022
StartActual
Jun 28, 2022
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Jun 2028was Jun 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2027
Sep 25, 2026
Study completion
Jun 2027→Jun 2028
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Dec 2026→Dec 2027
    Study completion Jun 2027→Jun 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05335252
Responsible party
Vehniah Tjong (Assistant Professor, Northwestern University) — Principal investigator
First posted
Apr 19, 2022
Start date
Jun 28, 2022
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Vehniah K Tjong, MD
principal investigator · Northwestern Feinberg School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion